Company & Sponsor Intelligence
Janssen Korea, Ltd., Korea
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials4
Recruiting0
Completed4
Countries1
Therapeutic footprint
adhdalzheimersepilepsypain_neuropathy
Indexed studies
NCT01682681An Observational Study to Evaluate Long-term Retention Rate of Topiramate in Participants With Epilepsy
epilepsy · COMPLETED
epilepsy · COMPLETED
NCT01819805A Study to Assess the Improvement of Pain and Health-Related Quality of Life in Patients With Chronic Non-Malignant Pain Taking Tramadol Hydrochloride and Acetaminophen
pain_neuropathy · South KoreaCOMPLETED
pain_neuropathy · South KoreaCOMPLETED
NCT01734395A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease
alzheimers · COMPLETED
alzheimers · COMPLETED
NCT01012622An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)
adhd · PHASE4
adhd · PHASE4
Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →